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Abstract
The gastrointestinal tract is structurally and functionally different from the vagina. Thus, the paradigm of topical microbicide
development and evaluation has evolved to include rectal microbicides (RMs). Our interest was to create unique RM
formulations to safely and effectively deliver antiretroviral drugs to mucosal tissue. RMs were designed to include those that
spread and coat all surfaces of the rectum and distal colon rapidly (liquid) and those that create a deformable, erodible
barrier and remain localized at the administration site (gel). Tenofovir (TFV) (1%) was formulated as an aqueous
thermoreversible fluid and a carbopol-based aqueous hydrogel. Lipid-based liquid and gel formulations were prepared for
UC781 (0.1%) using isopropyl myristate and GTCC (Caprylic/Capric Triglycerides), respectively. Formulations were
characterized for pH, viscosity, osmolality, and drug content. Pre-clinical testing incorporated ex vivo colonic tissue
obtained through surgical resections and flexible sigmoidoscopy (flex sig). As this was the first time using tissue from both
sources side-by-side, the ability to replicate HIV-1 was compared. Efficacy of the RM formulations was tested by applying the
products with HIV-1 directly to polarized colonic tissue and following viral replication. Safety of the formulations was
determined by MTT assay and histology. All products had a neutral pH and were isoosmolar. While HIV-1BaL and HIV-1JR-CSF
alone and in the presence of semen had similar replication trends between surgically resected and flex sig tissues, the
magnitude of viral replication was significantly better in flex sig tissues. Both TFV and UC781 formulations protected the
colonic tissue, regardless of tissue source, from HIV-1 and retained tissue viability and architecture. Our in vitro and ex vivo
results show successful formulation of unique RMs. Moreover, the results of flex sig and surgically resected tissues were
comparable suggesting the incorporation of both in pre-clinical testing algorithms.
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Introduction
Globally, the primary spread of HIV-1 is through heterosexual
sex and women bear the greatest burden of infections [1]. Early
efforts focused on prevention modalities that women could use
independently of their partner to protect themselves from
infection. Thus, the paradigm for microbicide development and
use was focused on vaginal products; gels women would use prior
to coitus independent of their partners consent to prevent the
acquisition of HIV-1 [2]. In developed countries, the epidemic is
spread primarily among those who engage in receptive anal
intercourse (RAI) [3]. Indeed, some areas of the United States
have incidence rates among black men who have sex with men
(MSM) that compare equally to those of the generalized HIV
epidemic in sub-Saharan Africa [4] and of marginalized MSM
populations in Asia and Africa [5]. Further, RAI has been an
underappreciated activity among heterosexual couples worldwide
and may contribute to the HIV-1 epidemic more than previously
thought [6–8]. Because of this, vaginal microbicides when
developed would be used by all persons wanting to protect
themselves from HIV-1 infection and would likely be used rectally.
However, the structure (luminal area, epithelium, and immune cell
numbers) and environment (pH and flora) of the gastrointestinal
tract is significantly different from the female genital tract.
Consequently, products made for the vagina may not be optimal
for rectal use.
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With the lack of effectiveness found in non-specific entry
inhibitors such as cellulose sulfate [9,10] and PRO 2000 [11,12]
and surfactants such as nonoxynol-9 [13–15], antiretroviral drugs
are currently the lead candidates being pursued for topical
microbicide development. Tenofovir (TFV) and UC781 are
representative of nucleotide reverse transcriptase inhibitor (NRTI)
and non-nucleoside reverse transcriptase inhibitor (NNRTI) drug
classes, respectively. Both drugs have been formulated as vaginal
microbicide aqueous gel products and have been evaluated in
clinical trials [16–19]. Additionally, both vaginal gels have been
evaluated clinically for rectal safety [20,21]. While no safety
concerns were noted in trial participants when either gel was used
vaginally, some of the participants using the vaginal TFV 1% gel
rectally exhibited gastrointestinal complications that included
abdominal bloating, pain/cramps, and defecation urgency [20].
These symptoms are reminiscent of hyperosmolar enemas. Indeed,
the vaginal TFV 1% gel was hyperosmolar and showed epithelial
sloughing in ex vivo mucosal tissue [22]. These data reinforce the
need for rectal-specific products – rectal microbicides (RMs) –
specifically designed for use during RAI [23].
The use of ex vivo mucosal tissue to evaluate the safety and
efficacy of HIV-1 prevention modalities has increased over the
past decade. Several laboratories now utilize colonic tissue in
addition to ectocervical tissue to test drug candidates and their
formulations (topical microbicides) for safety and effectiveness [24–
26]. Tissue is most often acquired as remainders from surgery [24–
26], but colonic tissue also has been collected by flexible
sigmoidoscopy (flex sig) [25]. The ability to use various sources
of tissue for testing has the potential to increase the efficiency of
product testing and reduce the time needed to acquire this
information, thus streamlining the testing process. To effectively
utilize flex sig tissue for microbicide testing, the tissue collected
from both procedures needs to show consistency in results. There
are several differences between resected and flex sig tissue that
make comparing important and include (i) the anatomical location
where the colon tissue is collected, (ii) the length of time between
procedure and transport to the laboratory, (iii) pre-existing
medical conditions and treatments, and (iv) the age of tissue
donor. To demonstrate that tissue acquired by either procedure
performs similarly in the ex vivo explant model, we compared the
ability to infect the tissues with HIV-1 and also the safety and
efficacy outcomes following exposure to novel rectal-specific
antiretroviral microbicide products.
Materials and Methods
Human tissue
Surgically resected and flex sig tissues were acquired through
approved protocols by the University of Pittsburgh (Pitt) Institu-
tional Review Board (IRB). The Pitt IRB specifically approved
both protocols: collection from patients undergoing surgery (IRB
# PRO0602024) and collection from healthy individuals (IRB #
PRO10070364). Normal human colonic tissue was acquired by
surgical resection from persons undergoing surgery for non-
inflammatory conditions (18 to 80 years old). The median age of
the patients was 64 years old (range 35–75). The patients signed a
general waiver for their surgical procedure which includes the use
of their tissue for research purposes. After clearance from
pathology, surgically resected tissue was collected by an ‘‘Honest
Broker’’ whose role was to de-link identifiable patient information
from the investigators. The Honest Broker also provided
generalized demographic information, such as location of colon,
age range, race, and gender of the patient. Flex sig tissues were
collected from persons (18 to 65 years old) recruited for the study.
The median age of the participants was 40 years old (range 19–61).
These participants were healthy individuals with no known
evidence of gastrointestinal disease. After signing a consent form,
20 biopsies were collected from the sigmoid colon, 15 cm from the
anal margin using Jumbo forceps (Radial Jaw 4, Boston Scientific,
Natick, MA) by a board-certified gastroenterologist. The flex sig
tissue was provided with study identifiers de-linking participant
information for the investigators. Regardless of procedure, tissue
was placed in cold transport medium (L-15 supplemented with
10% fetal calf serum, 100 mg/ml streptomycin, 100 U/ml
penicillin, 250 mg/ml amphotericin B, and 100 mM L-glutamine)
and processed within 90 minutes.
Rectal-specific microbicide products
Formulation preparation. Previously, four rectal specific
placebo products, namely, aqueous gel, aqueous liquid, lipid gel
and lipid liquid, were developed by our group [23]. These four
products possessed a wide range of physical and chemical
properties which could be utilized to formulate either a water
soluble or a water insoluble drug candidate as a solution thereby
providing a high concentration gradient for drug release. This
panel of placebo products served as the basis for formulation of the
hydrophilic drug (TFV, provided by CONRAD, Arlington, VA)
and the lipophilic drug (UC781, provided by CONRAD).
TFV aqueous gel (1%) was prepared as a carbopol 974
(Lubrizol, Cleveland, OH) and sodium carboxymethylcellulose
(Na CMC, high viscosity; Spectrum, New Brunswick, NJ) based
formulation. Briefly, a solution of the preservatives (methylparaben
and propylparaben) was prepared in purified water using heat (60–
75uC). TFV (1%) was then dissolved in the solution by addition of
NaOH (18% w/v) using an overhead propeller mixer (Model
RW20, IKA Works, Inc. Wilmington, NC). Carbopol 974P (0.5%)
and 1% Na CMC were added and mixed until dissolved. Then
0.1% disodium edetate and 2.5% glycerin were added and mixed
to dissolve. Finally, NaOH was added to neutralize the carbopol
for gel formation.
TFV aqueous liquid (1%) was formulated into a thermorever-
sible aqueous liquid. First, the preservative solution (methylpara-
ben and propylparaben) was prepared at 60–75uC and then
cooled to 8–10uC. Sodium citrate dehydrate NF (0.3%) (Spec-
trum), 2% glycerin (Spectrum) and 15% Poloxamer 407 (Pluronic
F127; BASF Corporation, Mt. Olive, NJ) were added while
stirring. TFV was added to the aqueous solution.
UC781 lipid gel (0.1%) was formulated into a lipid cream.
Briefly, UC781, 0.1% vitamin E acetate (Spectrum) and 0.2%
antioxidant butylated hydroxyanisole (Spectrum) were dissolved in
a lipid solvent, 74.8% caprylic/capric triglyceride (Crodamol
GTCC; Croda Inc., Edison, NJ). The lipid gelling agent, 24.8%
glyceryl stearate and PEG-75 stearate (GelotTM 64; Gattefosse,
Paramus, NJ) was then added into the lipid solvent containing
UC781.
UC781 lipid liquid (0.1%) was formulated into a lipid liquid.
Briefly, 94.8% isopropyl myristate (Crodamol IM; Croda) and
4.9% myristyl myristate (Crodamol MM; Croda) were heated to
60uC and stirred to dissolve using an overhead mixer. Antioxidant
0.2% butylated hydroxyanisole (Spectrum) and UC781 were
added and mixed to uniformity.
Formulation characterization. Appearance: Formulations
were evaluated by visual inspection for phase separation, color,
clarity, consistency and particulates in clear, glass scintillation
vials.
Drug content: TFV drug content was measured in triplicate
using an established high performance liquid chromatography
(HPLC) method. Briefly, a Dionex Ultimate 3000 system (Thermo
Pre-Clinical Testing of Rectal Microbicides
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Scientific, former Dionex, Bannockburn, IL) equipped with an
autosampler, photodiode array detector, and Chromeleon version
6.8 software were used with an Acclaim 120 A˚ (4.66150 mm,
3 mm) (Thermo Scientific, former Dionex) column. Separations
were done in an isocratic system using a mixture of 10 mM
K2HPO4 buffer solution containing 5 mM t-butylammonium
bisulfate (pH 5.7) and methanol at a ratio of 90:10. The flow rate
Figure 1. HIV-1 replication across four major areas of the colon. Tissues from the ascending, transverse, descending, and sigmoid colon were
evaluated for the ability of HIV-1BaL to infect and replicate. Tissues were set-up in polarized conditions and HIV-1 was applied to the apical, luminal
surface. After overnight culture, the tissues were washed and followed through day 21 of culture. HIV-1 replication (p24 ELISA) was monitored in the
basolateral supernatant collected every 3 to 4 days of culture. The data presented are a median of 7, 6 (ascending and sigmoid), and 4 (transverse and
descending) tissues 695% confidence interval.
doi:10.1371/journal.pone.0102585.g001
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was 1.0 ml/min. The wavelength was 260 nm. The linear range
was from 1 to 200 mg/ml.
UC781 drug content was measured in triplicate using the same
HPLC system as described above. The separation was achieved
using a gradient method on an Acclaim 120 A˚ (4.66150 mm,
3 mm) column. The initial mobile phase of acetonitrile:water at a
ratio of 75:25 was run for 10 min followed by a linear gradient
over 30 min to a final mobile phase of acetonitrile:water at a ratio
of 95:5. The linear range was from 1 to 250 mg/ml.
Viscosity: Rheological profiles were determined using a cone
and plate viscometer (Brookfield HADV III+ and LVDV III ultra,
Brookfield Engineering Laboratories, Middleboro, MA). Shear
stress over a range of shear rates from 0.1 rpm to 30 rpm was
recorded and both increasing and decreasing curves generated at
25 and 37uC. All viscosities reported were apparent viscosities
calculated as the ratio of shear stress to shear rate. For comparison
purposes, viscosities were calculated at a fixed shear rate of
10 rpm.
pH: The pH of the TFV aqueous gel formulation was measured
using a pH meter (Accumet AR 20, Fisher Scientific, Pittsburgh,
PA) equipped with a flat surface pH electrode (Beckman Coulter
Futura Flat Bulk Combination pH electrode, Fisher Scientific).
The pH of the TFV aqueous fluid formulation was measured with
the same instrument using a glass pH electrode (Accumet pH
electrode, Fisher Scientific). The pH meter was calibrated with
pH 4.0, 7.0 and 10.0 standards.
Osmolality: The osmolality of TFV aqueous formulations was
measured using a vapor pressure osmometer (Model # 5520;
Wescor, Inc, Logan, UT).
Short term stability. Studies were conducted for three
months to evaluate product stability over the time frame required
for colonic tissue evaluation. Gel formulations were packaged in
glass, straight sided jars. Opaque jars were used for UC781
formulations to protect the product from light. Liquid formula-
tions were packaged in glass Boston round bottles with poly-seal
caps. Packaged product samples were stored at 25uC/60% RH
and 40uC/75% RH. Testing at each stability time point included
appearance, viscosity, and drug content for all samples. Addition-
ally, pH and osmolality was tested for aqueous formulations.
Virus. HIV-1BaL working stock was made by diluting a
concentrated stock (Advanced Biotechnologies, Inc., Columbia,
MD). Additionally, an infectious molecular clone of HIV-1JR-CSF
was obtained from the AIDS Research and Reference Reagent
Program, DAIDS, NIAID, NIH. Stocks of the clone was made by
transfecting 293T cells and collecting the 48 h supernatant. HIV-
1BaL and HIV-1JR-CSF stocks were titrated in activated PBMCs
using the Reed & Muench method [27]. Virus aliquots were stored
at 280uC until used.
Polarized explants. The biopsies obtained from flex sig were
variable in size, but overall similar to the explants made from
surgical resections which were approximately 5 mm in diameter
63 mm in depth. Polarized explant cultures were set-up as
previously described [24]. Briefly, the tissue was placed with the
luminal side up resting on medium-soaked gelfoam in a transwell.
The edges around the explant were sealed with Matrigel (BD
Biosciences, San Jose, CA). Tissues were cultured with the luminal
surface at the air-liquid interface and 1 ml of medium (RPMI-
1640 medium supplemented with 5% human AB serum, 100 U/
ml IL-2 [Roche Applied Science, Indianapolis, IN], 100 mg/ml
streptomycin, 100 U/ml penicillin, and 100 mM L-glutamine,
0.5 mg/ml Zosyn and 2.5 mM Hepes) in the basolateral
compartment. For the first 24 h, the basolateral medium
contained 5 mg/ml of phytohemagglutinin-P (Sigma-Aldrich, St.
Louis, MO). Cultures were maintained at 37uC in a 5% CO2
atmosphere. Each study condition was assembled in duplicate. To
compare the collection procedures on HIV-1 infection, titrations
of virus were added to the apical surface either alone or with 50%
normal, pooled human semen (Lee BioSolutions, Inc., St. Louis,
MO). When the RM were tested, a 1:5 dilution of the aqueous
formulations (tenofovir 1% gel or liquid along with the
corresponding placebo) or neat lipid formulations (UC781 lipid
gel or liquid and the corresponding placebos) were mixed with the
virus before adding to the apical surface. Tissues were cultured
overnight, washed, and fresh culture medium replenished in the
basolateral compartment. Every 3 to 4 days, basolateral superna-
tant was collected and fresh medium replaced. The collected
Figure 2. HIV-1 replication in colonic tissue obtained through surgical resection and flexible sigmoidoscopy. Polarized cultures were
set-up in duplicate. Titrations of HIV-1BaL and HIV-1JR-CSF were applied to the apical surface and allowed to culture overnight. The following day, the
tissues were thoroughly washed and followed through day 21 of culture. HIV-1 replication (p24 ELISA) was monitored in the basolateral supernatant
collected every 3 to 4 days of culture. The data presented are the median695% confidence interval of 7 tissues for HIV-1BaL and 5 tissues for HIV-1JR-CSF
for surgical resections; and 12 tissues for HIV-1BaL and 9 tissues for HIV-1JR-CSF for flexible sigmoidoscopy.
doi:10.1371/journal.pone.0102585.g002
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Figure 3. The impact of semen on HIV-1 replication by colonic tissue. Tissues were set-up in duplicate in polarized cultures to evaluate the
effects of semen on HIV-1 infection (A) or on tissue viability/architecture (B). (A) HIV-1BaL or HIV-1JR-CSF was mixed with 50% whole semen and applied
to the apical surface and cultured overnight. The following day, the tissues were thoroughly washed and followed through day 21 of culture. HIV-1
replication (p24 ELISA) was monitored in the basolateral supernatant collected every 3 to 4 days of culture. The data presented are the median695%
confidence interval of 5 tissues for HIV-1BaL and HIV-1JR-CSF each for surgical resections; and 7 tissues for HIV-1BaL and 5 tissues for HIV-1JR-CSF for
flexible sigmoidoscopy. (B) 50% semen was added to the apical surface of surgical resections (SR) or flexible sigmoidoscopy (FS). As controls, medium
alone (untreated control) or medium containing a 1:5 dilution of a 3% nonoxynol-9 (N9)-containing gel were used. After an overnight culture, tissues
were washed with one piece further cultured in medium containing 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan for the MTT assay or the other
piece fixed in paraformaldehyde for hematoxylin and eosin staining. The MTT assay results are presented as scatter plots with the horizontal lines
denoting the mean 6 standard deviation of 5 independent tissues. The histology is representative of one of those tissues.
doi:10.1371/journal.pone.0102585.g003
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supernatant was stored at 280uC. HIV-1 replication was
monitored by p24 ELISA from the culture supernatants.
To investigate the possible impact of semen or rectal
microbicide products on tissue viability, surgically resected or flex
sig acquired colorectal tissues were placed in culture using our
polarized protocol. Tissues were exposed to semen or RM
overnight. As controls, tissue alone or tissue treated with a 1:5
dilution of a 3% nonoxynol-9 containing gel (Gynol II, Revive
Personal Products Company, Madison, NJ) were tested in parallel
in the same tissue donor. The next day, tissues were washed and
viability was evaluated using the MTT [1-(4,5-dimethylthiazol-2-
yl)-3,5-diphenylformazan] assay and architecture assessed by
histology [24].
Statistical analysis. Descriptive statistics were run on all
variables of interest. For continuous variables, sample means and
standard deviations were computed; for categorical variables,
sample proportions were calculated. Medians and ranges were also
included due to the non-normal nature of HIV-p24.
Linear mixed models were used to investigate the trajectory of
ln(HIV-p24) over time and how it relates to colon location, HIV
titration, effect of semen, and rectal microbicide efficacy. The
natural log transformation of the outcome was chosen due to the
highly right-skewed nature of the data.
For the colon location analysis, the linear mixed model included
predictors for ‘‘day of culture’’, colon location, their interaction,
and a random effect to account for correlated observations from
the same sample. The models for HIV titration and effect of semen
each had predictors for ‘‘day of culture’’, tissue collection method
(surgically resected versus flex sig), their interaction, and a random
effect. In addition, the models were run separately within each
combination of virus (HIV-1JR-CSF and HIV-1BaL) and titer (10
2,
103, and 104). Finally, the linear mixed model for rectal
microbicide efficacy includes predictors for ‘‘day of culture’’,
microbicide type (control versus microbicide versus placebo
version of microbicide), their interaction, and a random effect.
The microbicides (TFV aqueous gel, TFV aqueous fluid, UC781
lipid gel, and UC781 lipid liquid) and placebos were analyzed
separately for each of the flex sig and surgical resection methods.
Of primary interest in these statistical models was whether there
was a significant difference in p24 values across time (significant
interaction). If not, main effects of colon location, tissue collection
method, or rectal microbicide efficacy were investigated. Changes
in tissue viability (MTT assay) were determined by a Mann-
Whitney test (semen) or an ANOVA with Bonferroni’s Multiple
Comparison Test (product).
Each of the analyses was conducted at the 5% significance level
with no adjustments for multiplicity. All analysis was conducted in
SAS (Cary, NC) as well as GraphPad (GraphPad Prism 5, version
5.04).
Results
HIV-1 infection in surgically resected tissue
Throughout the colon are isolated lymphoid follicles which
serve as inductive sites for immune responses [28]. The number of
follicles generally increases toward the anus with the greatest
numbers found in the rectum [29,30]. Consequently, there may be
differences in HIV-1 replication across the colon. While several
laboratories use surgically resected tissue, none have investigated
potential differences in the ability to infect distinct areas of the
colon with HIV-1. Therefore, HIV-1 replication kinetics were
evaluated across the colon: ascending, transverse, descending, and
sigmoid (Fig. 1A). To note, no surgically resected rectal tissue was
obtained in our study. Colonic tissues were from patients (age
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ranges 30 to 79 years old). The number of transverse and
descending tissues (n = 4 each) available to compare were limited.
Overall, similar replication kinetics and magnitude of viral
replication were noted from the different locations of the colon
(P = .56) (Fig. 1B). Thus, location of tissue does not appear to
restrict HIV-1 infection and replication in surgically resected
tissue.
Comparing HIV-1 infection in surgically resected with flex
sig tissues
Tissue obtained from surgical resections is from donors that are
generally older than participants recruited for collection of flex sig
tissue. Moreover, surgically resected tissue is collected from
patients with medical conditions that may require treatment (for
example chemotherapy for cancer) and have a more prolonged
ischemic time (up to 3 hours) due to the required release from the
pathology department while flex sig tissue is collected immediately
from healthy participants. These differences led us to compare
HIV-1 replication kinetics between these tissue collection proce-
dures. Surgically resected and flex sig tissues were exposed to
titrations of HIV-1BaL and HIV-1JR-CSF (Fig. 2). Surgically
resected tissue replicated 104 TCID50 of HIV-1BaL to 4.7 log10
p24. This was similar to the 103 TCID50 (4.8 log10) and .1000-
fold better than the 102 TCID50 of HIV-1BaL (1.2 log10). Flex sig
tissue replicated the 104 and 103 TCID50 of HIV-1BaL to 5.2 log10
p24, while 102 TCID50 of HIV-1BaL replicated to 2.5 log10 p24.
The statistical model showed there were no differences in p24
trajectory between the tissue collection procedures at any of the
titrations (104: P = .7704; 103: P = .5123; 102: P = .6216). As
compared to HIV-1BaL, HIV-1JR-CSF is a T-cell tropic R5-using
virus and may better represent virus that is sexually transmitted
[31,32]. The peak HIV-1JR-CSF p24 for 10
4, 103 and 102 TCID50
(respectively) was 4.7, 4.5, and 0.9 log10 p24 for surgically resected
tissue compared to 5.1, 4.5, and 1.4 log10 p24 for flex sig tissue.
While the kinetics of replication for both viruses were similar, flex
sig tissue replicated HIV-1JR-CSF better than surgically resected
tissue at all titrations of virus (104: P = .0020; 103: P = .0355; 102:
P = .0363). In general, the 102 TCID50 of either virus resulted in
highly variable replication, confirming this dose of HIV-1 was
beyond the limit of reproducible infection.
Because HIV-1 infection occurs primarily through sex, HIV-1
infection was evaluated in the presence of semen. Surgically
resected and flex sig tissues were exposed to titrations of HIV-1 in
the absence or presence of 50% whole semen (Fig. 3A). Overall,
Table 2. Stability of rectal-specific microbicide formulations.
Formulation Condition/Interval (month) Drug content (%, w/w) Viscosity (cp) pH Osmolality (mmol/kg)
Tenofovir aqueous gel 25uC Initial 0.97160.026 3050 7.0 479
1 0.97260.004 3293 6.9 461
2 0.98360.008 3407 7.0 512
3 0.99960.007 3247 7.1 607
40uC 1 0.98960.017 3205 7.0 474
2 1.00260.012 3086 7.0 508
3 0.98460.036 2946 7.0 615
Tenofovir aqueous liquid 25uC Initial 0.99360.022 101 7.0 593
1 0.96460.059 103 7.1 585
2 1.00260.010 116 7.0 570
3 0.99360.021 108 6.9 676
40uC 1 0.97860.056 109 7.0 555
2 0.99960.035 116 6.9 613
3 0.98560.015 112 7.0 495
UC781 lipid gel 25uC Initial 0.09660.001 4329 –* –
1 0.09360.001 4122 – –
2 0.09160.001 4256 – –
3 0.09160.002 4529 – –
40uC 1 0.09360.001 4246 – –
2 0.09360.001 4298 – –
3 0.08960.002 4445 – –
UC781 lipid liquid 25uC Initial 0.09660.002 5.3 – –
1 0.09660.001 5.3 – –
2 0.09460.003 5.2 – –
3 0.09560.001 5.3 – –
40uC 1 0.09460.001 5.3 – –
2 0.09360.002 5.2 – –
3 0.09260.003 5.3 – –
*not required.
doi:10.1371/journal.pone.0102585.t002
Pre-Clinical Testing of Rectal Microbicides
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e102585
Figure 4. Rectal-specific microbicide (RM) products protect surgically resected colonic tissue from HIV-1 infection and are safe.
Colonic tissue obtained through surgical resections was used to create polarized explant cultures. The explants were set-up in duplicated. (A) Efficacy:
Tenofovir (TFV) aqueous-based RMs were diluted 1:5 in medium with HIV-1BaL and applied to the apical surface. The UC781 lipid-based RMs were
used neat and mixed with HIV-1BaL, and then applied to the apical surface. The corresponding placebo products were handled in a similar fashion.
After an overnight culture, the tissues were thoroughly washed and followed through day 21 of culture. HIV-1 replication (p24 ELISA) was monitored
in the basolateral supernatant collected every 3 to 4 days of culture. The data presented are the median 695% confidence interval of 5 independent
tissues for each treatment. (B) Tissue viability: After an overnight culture with the indicated RM product, medium alone (untreated control) or
medium containing a 1:5 dilution of a 3% nonoxynol-9 (N9)-containing gel, tissues were washed with one piece further cultured in medium
containing 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan for the MTT assay or the other piece fixed in paraformaldehyde for hematoxylin and
eosin staining. The MTT assay results are presented as scatter plots with the horizontal lines denoting the mean 6 standard deviation of 5
independent tissues. The histology is representative of one of those tissues.
doi:10.1371/journal.pone.0102585.g004
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Figure 5. Rectal-specific microbicide (RM) products protect colonic tissue obtained through flexible sigmoidoscopy from HIV-1
infection and are safe. Colonic tissue obtained through flexible sigmoidoscopy was used to create polarized explant cultures. The explants were
set-up in duplicate. (A) Efficacy: Tenofovir (TFV) aqueous-based RMs were diluted 1:5 in medium with HIV-1BaL and applied to the apical surface. The
UC781 lipid-based RMs were used neat and mixed with HIV-1BaL, and then applied to the apical surface. The corresponding placebo products were
handled in a similar fashion. After an overnight culture, the tissues were thoroughly washed and followed through day 21 of culture. HIV-1 replication
(p24 ELISA) was monitored in the basolateral supernatant collected every 3 to 4 days of culture. The data presented are the median695% confidence
interval of 3 to 5 independent donors for each treatment. (B) Tissue viability: After an overnight culture with the indicated RM product, medium alone
(untreated control) or medium containing a 1:5 dilution of a 3% nonoxynol-9 (N9)-containing gel, tissues were washed with one piece further
cultured in medium containing 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan for the MTT assay or the other piece fixed in paraformaldehyde for
hematoxylin and eosin staining. The MTT assay results are presented as scatter plots with the horizontal lines denoting the mean 6 standard
deviation of 4 independent donors. The histology is representative of one of those donors.
doi:10.1371/journal.pone.0102585.g005
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HIV-1BaL and HIV-1JR-CSF replication was reduced in the
presence of semen regardless of tissue source. HIV-1BaL at 10
3
TCID50 and HIV-1JR-CSF at 10
4 and 103 TCID50 with semen
exhibited delays in virus replication, but by day 21 the cultures had
similar p24 levels as tissue exposed to HIV-1 in the absence of
semen. For both viruses at 102 TCID50, viral replication was
reduced in both tissues in the presence of semen. Similar to HIV
titration without semen, the p24 trajectories in HIV-1BaL did not
differ between collection procedures (104: P = .5062; 103:
P = .2936; 102: P = .1426), but flex sig tissues had consistently
greater viral replication for 103 and 102 TCID50, regardless of day
(104: P = .4862; 103: P = .0460; 102: P = .0050). For HIV-1JR-CSF,
p24 trajectories did differ for 104 TCID50 (P = .0340), but further
investigation found no differences at any day of culture. Overall,
for the 102 TCID50 titrations, flex sig had greater viral replication
than surgically resected tissue independent of semen across days
(HIV-1BaL: P = .0050; HIV-1JR-CSF: P = 0.0110). The lack of
enhancement in HIV-1 replication by semen could not be
attributed to loss of tissue viability as both surgically resected
and flex sig tissues retained mitochondrial activity, as determined
by the MTT assay, and showed retention of their architecture
(Fig. 3B).
Development and characterization of rectal-specific
microbicide formulations
These data show reproducible HIV-1 infection from the four
major areas of the colon and between surgically resected and flex
sig tissue. Therefore, use of either tissue should demonstrate
comparable data when evaluating RMs. To test our hypothesis,
four rectal-specific microbicide formulations were developed
representing either a gel or liquid dosage form containing TFV
or UC781. These four products possess distinct physicochemical
properties representing a wide range for rectal-specific microbicide
products (Table 1). Given the hydrophilic nature of TFV, TFV
formulations were aqueous-based. Conversely, based on the
hydrophobicity of UC781, those formulations were of a lipid
nature. The TFV aqueous gel exhibited shear thinning and non-
Newtonian pseudoplastic behavior. In a shear thinning system,
viscosity decreases as the applied shear to the product is increased
and a non-Newtonian fluid exhibits variable viscosity over a range
of shear rates. The TFV aqueous liquid utilized Poloxamer to
create a thermoreversible product and exhibited Newtonian
rheological profile at 25uC with no viscosity change over a range
of shear rates. However, it exhibited shear thinning non-
Newtonian pseudoplastic rheological profile at 37uC. The
rheological profile of the UC781 lipid gel was shown to be shear
thinning, non-Newtonian and thixotropic with a lower viscosity at
37uC. In a thixotropic system, the viscosity decrease observed as
increased shear is applied requires time to return to original values
as the shear is removed. In contrast, the UC781 lipid liquid was
Newtonian, showing constant viscosity over a range of shear rates
with similar viscosities observed at 25uC and 37uC. The pH of
TFV aqueous gel and liquid were 7.0, which approximates the
physiological pH of the rectal compartment [33]. The TFV
aqueous gel and liquid were 479 mmol/kg and 593 mmol/kg,
respectively, indicating they were ,2-fold above normal physio-
logic osmolalities (,300 mmol/kg). The stability data generated
for all formulations at 25uC/60% RH and 40uC/75% showed all
products to remain within target specifications (Table 2). Stability
data demonstrated product integrity for the time frame required
for colonic tissue explant evaluation.
Rectal-specific microbicide evaluation for safety and
efficacy against HIV-1
The TFV and UC781 formulations were evaluated using
surgically resected and flex sig tissue for the ability to block HIV-1
infection and their safety in mucosal tissue. In surgically resected
tissue, there was a .2 log10 reduction of p24 between the active
rectal microbicide formulations compared to the HIV-1 only
treated tissues (Fig. 4A). The TFV and UC781 formulations all
provided protection against HIV-1 infection as shown by a
significant separation of HIV-1 p24 (P#.05) by day 10 of culture.
The aqueous and lipid gel placebos both showed a partial
reduction of HIV-1 infection in the tissue, but none of the placebos
significantly impacted HIV-1 infection of the tissue (P..05). The
MTT assay and histology showed both formulations of TFV and
UC781 retained surgically resected colonic tissue viability and
maintained tissue architecture (Fig. 4B). Nonoxynol-9 treatment
(toxicity control) resulted in a significant reduction in tissue
viability compared to the untreated tissue (P#.01). Histologically,
the tissue was stripped of the epithelium and the lamina propria
was acellular compared to the control tissue.
Using flex sig biopsies, consistent efficacy results were found
when compared to the surgically resected tissue. A .2.5 log10
reduction of p24 was noted from the TFV and UC781 treated
tissues to HIV-1 only tissues (Fig. 5A). The TFV and UC781
formulations all provided protection against HIV-1 infection as
shown by a significant separation of HIV-1 p24 (P#.05) by day 10
of culture. While a decrease in p24 was noted for tissue treated
with the placebo gels and liquids, none were significantly different
from the HIV-1 control tissues (P..05). Safety testing was
performed on the TFV aqueous gel and UC781 lipid liquid along
with their respective placebos (Fig. 5B). Flex sig tissue viability was
retained after exposure to the active and placebo formulations.
Nonoxynol-9 significantly decreased tissue viability (P,.05).
Histologically, the formulations showed no impact on epithelial
integrity while the nonoxynol-9-treated tissue showed stripping of
the epithelium and necrosis of the lamina propria. These data are
consistent with the findings from the safety testing using surgically
resected tissue (Fig. 4B).
Discussion
Because the rectum and lower gastrointestinal tract are
structurally and functionally different from the vaginal vault,
RM design has had two different approaches to establishing an
effective rectally administered microbicide [23]. The first ap-
proach creates a formulation that spreads and coats all surfaces of
the rectum and distal colon (liquid) rapidly prior to RAI and
exposure to infected secretions. The second approach creates a
deformable, erodible barrier that would remain localized at the
administration site (semi-solid gel). These formulations must allow
drugs to be solubilized to permit a pharmacological response. We
evaluated the formulation of two drug candidates; one hydrophilic
(TFV) and the other hydrophobic (UC781), using colonic tissue
collected via different methods. The differing chemical nature of
these two drug candidates permitted study of aqueous- and lipid-
based products formulated into both liquids and gels. The
rheological profile of a rectal product dictates its behavior with
respect to mucosal coating and product erosion following product
administration. The liquid products were Newtonian with respect
to their flow behavior irrespective of whether they were aqueous or
lipid based. Such a product would exhibit no change in viscosity
with increased shear force. Since it is intended that liquid products
would be ‘‘enema-like’’ and deliver drug further into the rectal
compartment, a Newtonian product would easily spread over the
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mucosal surface. Conversely the gel products exhibited non-
Newtonian behavior. Such a product requires introduction of
shear to induce flow. Hence, the gel products would form an
erodible barrier in which the product would remain localized and
shear forces such as sexual intercourse would facilitate spreading.
Developing both product types allowed for study of differing
product distribution profiles to deliver TFV and UC781 to areas
that would be exposed to potential infectious semen. Both TFV
and UC781 RM formulations prevented HIV-1 infection in
mucosal tissue, regardless of tissue source, and retained tissue
viability. These data support further clinical testing of these RM
products. It is hoped that rectal-specific formulations will be well
tolerated in the vaginal compartment because the ideal microbi-
cide formulation should have dual compartment safety and
effectiveness.
Topical microbicide evaluation relies on a testing algorithm to
define product activity and safety [22,34,35]. More researchers are
now incorporating mucosal tissue for product evaluation into their
algorithms. The ex vivo mucosal tissue typically has been acquired
from surgical resections. For colonic tissue, surgical resections are
often obtained from an older population who has undergone
treatment for colorectal cancer. Acquisition of this tissue is
dependent on an opportunistic surgical schedule and clearance
from pathology. This makes tissue procurement unpredictable and
prolongs the ischemic time (time from surgery to placement into
transport medium). These challenges can be overcome by using a
younger, healthier population of participants to obtain flex sig
biopsies which may more accurately reflect persons who would be
the primary users of topical microbicides. Despite requiring active
recruitment, flex sig tissue allows for immediate retrieval of tissue
from pre-scheduled appointments. The virus that is sexually
transmitted uses the CCR5 co-receptor. Therefore, the HIV-1
traditionally used to infect mucosal tissue for topical microbicide
evaluation has been HIV-1BaL likely because it was easily
accessible and one of the few viral isolates at the time that used
CCR5 [22,24,25]. HIV-1BaL was isolated from infected macro-
phages [36] and has been propagated in this cell type for almost 30
years. Other viruses including primary viral isolates and CXCR4-
using HIV-1 have been used for infection of mucosal tissue [24,37]
and show similar or slightly better replication as compared to
HIV-1BaL. In this study, HIV-1 infection was compared between
tissue types using HIV-1BaL and HIV-1JR-CSF. HIV-1JR-CSF is a
primary isolate (molecular clone) with a predilection for infecting
T cells as compared to macrophage [32]. This may better
represent the virus that is sexually transmitted as the founder
population of infected cells is likely T cells [38,39]. Infection of
surgically resected and flex sig tissue showed similar replication
kinetics for both viruses. However, the magnitude of HIV-1
replication in flex sig tissue was greater as compared to the
surgically resected tissue by 0.4 log10 at the highest virus titer and 2
log10 at the lowest virus titer. While the magnitude of viral
replication was significantly better for flex sig tissue, overall our
findings show similar trends between surgically resected and flex
sig tissues for HIV-1 infection and inhibition by rectal-specific
microbicide formulations. These data show surgically resected and
flex sig colonic tissue, while not identical, can be infected with HIV
and should allow for greater options in testing microbicide
products.
Typically semen delivers HIV-1 to the mucosa. Semen is a
bioactive secretion containing immune cells, soluble factors, and
other molecules [40–48] that have been shown to inhibit or
enhance HIV-1 infection ex vivo independently of the pH [49,50].
Using whole semen at a 50% concentration did not enhance HIV-
1 infection for either surgically resected or flex sig tissue. We chose
to use 50% whole, pooled semen because whole semen normally
will be present during coitus and likely modestly diluted in other
mucosal secretions (cervicovaginal and rectal fluids). Semen
includes several soluble factors; one of them being IL-7, which is
a central cytokine for T cell homeostasis [51]. Our culture
incorporates IL-2 in the medium to support T cell viability so the
additional effect of IL-7 on HIV-1 replication [47] may not be
apparent in our model. Semen enhancing viral infection (SEVI)
was shown to increase HIV-1 infection/replication in tonsil tissue
when HIV-1 was applied at a suboptimal dose [43]. In our model,
102 TCID50 of HIV-1BaL and HIV-1JR-CSF infects tissue incon-
sistently. When HIV-1 was applied in the presence of 50% semen,
no increase in HIV-1 infection/replication or improved consis-
tency of infection was found despite showing retention of tissue
viability. Moreover pooled semen was used in the experiments
presented here to reduce donor variability, thus the SEVI activity,
attributed to amyloid fibrils formed by the prostatic acidic
phosphatase fragments, is likely diminished because it has been
shown to be donor specific [45]. Thus the competing inhibiting
[40,42,46,48] and enhancing [41,43,45,47] activity of whole
semen may have a net neutral effect on HIV-1 infection in
mucosal tissue ex vivo.
The primary reason for evaluating surgically resected and flex
sig tissues is to incorporate either tissue source interchangeably for
rectal microbicide evaluation. To this end, novel RM formulations
of TFV and UC781 were evaluated and compared in both tissue
types. These formulations represent very different products,
aqueous and lipid, with different rheological properties. As
compared to topical microbicides that were designed for vaginal
use, these products have a neutral pH (aqueous formulations only)
and are slightly above isoosmolar [23]. Hyperosmolar gels when
used rectally have been shown to strip the colonic epithelium and
result in bowel urgency and abdominal bloating [20,52]. These
adverse events could lead to lack of product use. Further, in vitro
testing showed that hyperosmolar microbicides [22] and lubricants
[53] induced epithelial sloughing of the colonic epithelium and
negligible loss in tissue viability. This gives some credence that the
ex vivo model may reflect actual product use. The rectal-specific
microbicides evaluated here showed retention of viability and
architecture by both tissue sources. This likely reflects the near
isotonic nature of the formulations. Both TFV and UC781
formulations prevented HIV-1 infection of surgically resected and
flex sig tissues. This is the first time flex sig tissue has been used to
evaluate topical microbicides ex vivo. Collectively, our data
suggest these rectal-specific topical microbicide formulations
should be safe and could reduce the acquisition of HIV-1 infection
when used properly. Further testing is warranted to fully ascertain
the safety and potential efficacy in early phase 1 clinical trials that
incorporate the ex vivo challenge assay to provide linkages
between drug distribution (pharmacokinetics) and drug activity
(pharmacodynamics) [20,21].
Because mucosal tissue contains HIV-1 target cells in physio-
logically relevant ratios, it provides an integrated model for
understanding HIV-1 infection and product testing [54]. Howev-
er, there are limitations [54,55] in the use of mucosal tissue which
include: i) loss of mucus and flora, ii) absence of blood supply with
loss of hormonal control and capacity to recruit immune cells, and
iii) loss of tissue architecture after ,36h [24,25]. Knowing these
obstacles, mucosal tissue obtained from surgically resected and flex
sig procedures provided comparable results in terms of HIV-1
infection, responses to semen, and the ability of RM formulations
to prevent HIV-1 infection. The use of tissue collected from
surgical resections or flex sig allows expansion of HIV-1
prevention product testing.
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